Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prevention of Venous Thrombo Embolism (VTE).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Inclusion_Criteria~* Acute symptomatic deep vein thrombosis (DVT)~* Pulmonary embolism (PE) 3-12 months prior to screening, which has been documented by objective testing~Exclusion criteria:~Exclusion_Criteria~* Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more weeks during the 3-12 months of treatment for the prior VTE.~* Patients who in the investigators judgement are perceived as having an excessive risk of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) \> 2x ULN~* Severe renal impairment (estimated creatinine clearance \<= 30 ml/min)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: EXPERIMENTAL): Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
- Warfarin (INR of 2.0-3.0) (Type: ACTIVE_COMPARATOR): Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).